title: Plasma sLOX-1 is a potent biomarker of clinical remission and disease activity in patients with seropositive RA.
abstract: OBJECTIVE
  Soluble lectin-like oxidized low-density lipoprotein receptor 1 (sLOX-1) is present in the circulation and synovial fluid in patients with rheumatoid arthritis (RA). The aim of this study was to assess whether sLOX-1 level is associated with clinical remission and disease activity in patients with RA.
  
  
  METHODS
  Clinical and laboratory data were analyzed for 282 patients with RA. Plasma sLOX-1 level was measured by enzyme-linked immunosorbent assay (ELISA). The remission status and sLOX-1 levels were compared between four groups of patients based on the positivity of rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPAs). Relationships between sLOX-1 level and the 28-joint Disease Activity Score with erythrocyte sedimentation rate (DAS28-ESR) were analyzed by multivariate logistic regression.
  
  
  RESULTS
  The patients in the RF + ACPA + group tended to exhibit higher sLOX-1 levels when compared to the other three groups. In the RF + ACPA + group, the sLOX-1 level was significantly higher in the non-remission group than in the remission group, irrespective of treatment. Multivariate logistic regression showed significant correlations between sLOX-1 level and DAS28-ESR.
  
  
  CONCLUSIONS
  sLOX-1 level might be a useful biomarker for assessing clinical remission and disease activity in double-positive RA patients.
authors.affiliation: a Department of Orthopedic Surgery .|b Department of the Control for Rheumatic Diseases , and.
authors.forename: Masahiro
authors.initials: M
authors.lastname: Ishikawa
authors.affiliation: a Department of Orthopedic Surgery .
authors.forename: Hiromu
authors.initials: H
authors.lastname: Ito
authors.affiliation: a Department of Orthopedic Surgery .|b Department of the Control for Rheumatic Diseases , and.
authors.forename: Moritoshi
authors.initials: M
authors.lastname: Furu
authors.affiliation: b Department of the Control for Rheumatic Diseases , and.
authors.forename: Motomu
authors.initials: M
authors.lastname: Hashimoto
authors.affiliation: b Department of the Control for Rheumatic Diseases , and.
authors.forename: Takao
authors.initials: T
authors.lastname: Fujii
authors.affiliation: a Department of Orthopedic Surgery .
authors.forename: Akinori
authors.initials: A
authors.lastname: Okahata
authors.affiliation: c Department of Rheumatology and Clinical Immunology , Kyoto University Graduate School of Medicine , Kyoto , Japan.
authors.forename: Tsuneyo
authors.initials: T
authors.lastname: Mimori
authors.affiliation: a Department of Orthopedic Surgery .
authors.forename: Shuichi
authors.initials: S
authors.lastname: Matsuda
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001172:Arthritis, Rheumatoid / Q000097:blood* / Q000175:diagnosis; D001323:Autoantibodies / Q000097:blood; D015415:Biomarkers / Q000097:blood; D001799:Blood Sedimentation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010456:Peptides, Cyclic / Q000276:immunology; D012074:Remission Induction; D012217:Rheumatoid Factor / Q000097:blood; D051127:Scavenger Receptors, Class E / Q000097:blood*; D012720:Severity of Illness Index
chemical_list: D001323:Autoantibodies; D015415:Biomarkers; C495137:OLR1 protein, human; D010456:Peptides, Cyclic; D051127:Scavenger Receptors, Class E; C487763:cyclic citrullinated peptide; D012217:Rheumatoid Factor
keywords: Anti-citrullinated protein antibodies; Lectin-like oxidized low-density lipoprotein receptor 1; Rheumatoid arthritis; Rheumatoid factor